



**The Executive Office of Health & Human Services  
Center for Operations and Pharmacy Management**

**Pharmacy and Therapeutics Committee Meeting Minutes**

**Tuesday, December 3, 2013**

**8:00 AM**

**HP Enterprise Services**

**301 Metro Center Blvd, Room 203**

**Warwick, Rhode Island 02886**

**P & T Members Present:** Greg Allen, MD  
Scott Campbell, RPh  
Dave Feeney, RPh, Chairperson  
Rita Marcoux RPh, Co-Chairperson  
Richard Wagner, MD  
Kristina Ward, PharmD

**P & T Members Absent:** Chaz Gross, NAMI  
Matt Salisbury, MD

**Others Present:** Ann Bennett (HP Enterprise Services)  
Cathy Cordy, RPh (EOHHS)  
Jerry Fingerut, MD (Xerox)  
Karen Mariano, RPh (HP Enterprise Services)  
Kathryn Novak, RPh (Magellan Medicaid Administration)  
Joe Paradis, RPh (HID)

**Others Absent:** Deidre Gifford, MD, (Xerox)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:08am.

The September 2013 meeting minutes were reviewed and by vote were accepted as presented.

Election of committee officers and committee members. Motion made and accepted. Committee members accepted reelections.

**Public testimony included the following speakers and presentation topics:**

1. Jean Houtchens, Provider to pediatric and adult CF
2. Neil Marotta, Pfizer
3. Tom Algozzine, Novartis
4. Dan Foley, Boehringer Ingelheim
5. Ray Lancaster, Gilead
6. Christiane Arcever, Merck
7. Drew Revel, Genzyme

**Magellan Medicaid Administration presented the following categories for therapeutic class reviews with discussion from the committee.**

1. Anticonvulsants – 80.9% category compliance. Two new agents and several new generics; safety updates and two products with new indications. Motion to accept as the recommendations as presented – passes unanimously.

2. Antidepressants, Other – new generic and branded generic for venlafaxine ER – they are bioequivalent. New agent, Khedezla. Category compliance at 89.9%. Suggestion to include Cymbalta® within this category. Motion made, accepted; discussion. Amendment for Prestique, to have venlafaxine failure first. Motion made to accept recommendations with the amendment; – passes unanimously.
3. Antidepressants, SSRI – Brisdelle in this category (post-menopausal women). Compliance at 90%. Motion to accept as the recommendations as presented – passes unanimously.
4. Neuropathic Pain – new generic lidocaine patch; Category compliance 75.8%. New guidelines for treatment. Motion to accept as the recommendations as presented – passes with one abstention. Re-look at these PA guidelines during 2014.
5. NSAIDS - Motion to accept as the recommendations as presented – passes unanimously.
6. Platelet Inhibitors - Motion to accept as the recommendations as presented – passes unanimously.
7. Antianginal & anti-ischemic agents - Single agent group. Motion to accept as the recommendations as presented – passes unanimously
8. Antihypertensive, sympatholytics –New category for RI. Prior meeting discussed guanfacine and clonidine for treatment of ADHD. Motion to accept as the recommendations as presented – passes unanimously.
9. Angiotensin Modulators & combinations- Motion to accept as the recommendations as presented – passes unanimously
10. Beta Blockers – No new information. Motion to accept as the recommendations as presented – passes unanimously.
11. Calcium Channel Blockers – One new product used in critical care setting. Motion to accept as the recommendations as presented – passes unanimously
12. Lipotropics, Other – Three new products in the category, new generics and updated guidelines. Motion to accept as the recommendations as presented – passes unanimously
13. Lipotropics, Statin - FDA safety update. No changes in the category. Motion to discuss category; is there a message to notify the prescriber when high dose therapy occurs? Motion to accept as the recommendations as presented – passes unanimously
14. Antibiotics, Inhaled – New product, Bethkis, new generic and new device, Tobi Podihaler. Discussion to start a treatment naïve patient start on TOBI. Motion to accept as the recommendations as presented – passes unanimously.
15. Pulmonary Arterial Hypertension Agents – Two new products, Adempas and Opsumit. . Motion to accept as the recommendations as presented – passes unanimously.

Confirm and post meeting date. Tentative meeting dates for 2014 include:  
April 8<sup>th</sup>, June 3<sup>rd</sup>, August 26<sup>th</sup> and December 3<sup>rd</sup>.

As always, the meetings will begin at 8:00 AM.

The meeting adjourned at 10:05 AM.

#### DUR Board

1. take up the navigators product inclusion; note that based on plan, gold, platinum, etc coverage of the drug and the copays varies
2. Review angina patients
3. Step for Prestique, fail venlafaxine first
4. Step therapy needed for Brisdelle
5. Can DUR track savings when move from warfarin to newer product?
6. MCO coverage of Xarelto and Pradaxa?